Established Organotypic 3D Assay Platforms
Human Pancreatic Islets For The Study Of Type 2 Diabetes
Using our proprietary OrganDOT™ platform, Asterand Biosciences developed the isletOrganDOT model.
Prepared from readily available, high-quality fresh human pancreatic islets
- Contain representative islet cell populations, recapitulating islet morphology, gene expression and function
- Consistent GSIS responses achieved in OrganDOT cultures from ~50 donors together with reliable standard secretagogue-mediated potentiation of GSIS
- Valuable for studying a variety of pharmacologically-relevant mechanisms, including characterization of novel GPR40 agonists
- Long-term viability of OrganDOT cultures enables sequential or chronic compound testing
The advancements in functionality, robustness, throughput, and study design enabled by the isletOrganDOT model provide relevant human data on the effects of test compounds on islet function in a rapid and reproducible manner.
Reliable glucose-stimulated insulin secretion (GSIS) from isletOrganDOT cultures.
Consistent and robust stimulation of insulin secretion in response to increased glucose concentrations across multiple donors.
Reproducible enhancement of GSIS reponses with secretagogues.
Enhanced GSIS response by a standard secretagogue, exendin-4, across multiple donors. Secretagogue responses also demonstrated for GLP-1, glibenclamide, glimepiride, forskolin and novel GPR40 agonists.
Human Bronchial Epithelial Cells For The Study Of Respiratory Function
Asterand Bioscience has extensive experience in the preparation of organotypic cultures of human bronchial epithelium, using air-liquid interface (ALI) conditions to generate highly differentiated, mucociliary cultures that mimic many of the features of the airway epithelium. This platform allows us to establish appropriate in vitro assays for profiling the functional activity of novel therapeutics.
- Human bronchial epithelial cells (HuBEC) prepared from high quality fresh lung
- Cryopreserved HuBEC inventory for rapid project turnaround
- Established assay endpoints include
- Release of inflammatory mediators
- Mucous (goblet) cell hyperplasia
- Mucus secretion
- Squamous cell development
- Changes in gene expression
- Changes in barrier function
- HuBECs available from donors without respiratory disease and from donors with asthma, COPD or cystic fibrosis
- Potential to reveal differential effects of novel therapeutics on cells from non-diseased and diseased donors
Phase contrast photomicrograph of differentiated HuBEC in ALI culture.
Transverse section of HuBECs in ALI culture stained with H&E.
Columnar phenotype and ciliated surface are hallmarks of a fully differentiated phenotype.
Inhibition of mucin secretion by rottlerin. Goblet cell hyperplasia and increased mucin secretion can be induced by incubation with IL-13.